Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.

Volume: 146, Issue: 4, Pages: 485 - 493
Published: Apr 1, 2022
Abstract
Measurable (minimal) residual disease (MRD) is an independent prognostic factor for survival outcomes in patients with lymphoid and plasma cell malignancies and has been incorporated into consensus criteria regarding treatment response, strategy, and clinical trial endpoints. clonoSEQ (a next-generation sequencing [NGS]-MRD assay) uses multiplex polymerase chain reaction and NGS to identify clonotypic rearrangements at the immunoglobulin (Ig) H,...
Paper Details
Title
Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Published Date
Apr 1, 2022
Volume
146
Issue
4
Pages
485 - 493
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.